Polycythemia: all 183 studies

Page 1 of 2. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• The Effect Of Lisinopril On PolycythemiaRecruitingNCT07594535Phase 4
• Safety and Tolerability of ZE74-0282 in Healthy VolunteersRecruitingNCT07527221Phase 1
• Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia VeraNot yet recruitingNCT07341048Not applicable
• Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family HistoryNot yet recruitingNCT06923670Not applicable
• POlycythemia, Proteins and ErYthropoiesisRecruitingNCT06905106
• EVAluation of Erythrocytosis PRospEctive Cohort STudyNot yet recruitingNCT06785870
• Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisRecruitingNCT06770842Phase 2
• A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraRecruitingNCT06752746Phase 1
• Efficacy and Safety of Peginterferon in ET and PV.RecruitingNCT06734637Not applicable
• Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia VeraRecruitingNCT06516406
• Blood Viscosity in Polycythemia PatientsRecruitingNCT06421025
• Real-world Ruxolitinib Experience in PVNot yet recruitingNCT06251102
• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
• CPAP Effect on the Polycythemia in Patients With Obstructive Sleep ApneaRecruitingNCT06089603Phase 4
• A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisRecruitingNCT06073847
• 129Xe MRI CardiopulmonaryRecruitingNCT06038630Phase 2
• Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis.RecruitingNCT05993065
• Real World Evidence of Fedratinib Effectiveness in MFRecruitingNCT05883904
• Asian Myeloproliferative Neoplasm (MPN) RegistryRecruitingNCT05882773
• Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 2
• Effect of Phlebotomy on Heartrate in Polycythemia PatientsRecruitingNCT05396170
• Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingNCT04878003Phase 2
• Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsRecruitingNCT04655092Phase 3
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentRecruitingNCT03662126Phase 2/3
• Myeloproliferative Neoplastic Diseases Observatory From BrestRecruitingNCT02897297
• Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
• Molecular Biology of Polycythemia and ThrombocytosisRecruitingNCT00722527
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibCompletedNCT04884191Phase 2Results posted
• Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisTerminatedNCT04854096Phase 2Results posted
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia VeraTerminatedNCT03287245Phase 2Results posted
• Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)CompletedNCT03136185Phase 1/2Results posted
• PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsCompletedNCT03065400Phase 2Results posted
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseTerminatedNCT02436135Phase 1Results posted
• Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisTerminatedNCT02421354Phase 2Results posted
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.CompletedNCT02292446Phase 3Results posted
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibTerminatedNCT02226172Phase 2Results posted
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2Results posted
• Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3Results posted
• LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisCompletedNCT02098161Phase 2Results posted
• A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisCompletedNCT02087059Phase 3Results posted
• Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaTerminatedNCT02055781Phase 3Results posted
• Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.CompletedNCT02038036Phase 3Results posted
• A Phase 2 Study of RO7490677 In Participants With MyelofibrosisCompletedNCT01981850Phase 2Results posted
• Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedNCT01969838Phase 3Results posted
• A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia VeraCompletedNCT01901432Phase 1/2Results posted
• Ruxolitinib Prior to Transplant in Patients With MyelofibrosisTerminatedNCT01790295Phase 2Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• Pacritinib Versus Best Available Therapy to Treat MyelofibrosisTerminatedNCT01773187Phase 3Results posted
• HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETTerminatedNCT01668173Phase 2Results posted
• Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyCompletedNCT01632904Phase 3Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.CompletedNCT01493414Phase 3Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFCompletedNCT01392443Phase 2Results posted
• Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisCompletedNCT01369498Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Anti-TGF-beta Therapy in Patients With MyelofibrosisTerminatedNCT01291784Phase 1Results posted
• Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)CompletedNCT01259856Phase 3Results posted
• Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)CompletedNCT01243944Phase 3Results posted
• Study of SB939 in Subjects With MyelofibrosisCompletedNCT01200498Phase 2Results posted
• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia VeraTerminatedNCT01038856Phase 2Results posted
• Pomalidomide for Myelofibrosis PatientsCompletedNCT00946270Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary MyelofibrosisTerminatedNCT00931762Phase 2Results posted
• Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia VeraCompletedNCT00928707Phase 2Results posted
• Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesCompletedNCT00910728Phase 1Results posted
• Dasatinib in Polycythemia VeraTerminatedNCT00538980Phase 2Results posted
• Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
• Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00445744Not applicableResults posted
• Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Lenalidomide and Prednisone in Treating Patients With MyelofibrosisCompletedNCT00227591Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsCompletedNCT06371573
• Clinical and Laboratory Characteristics of Polycythemia VeraCompletedNCT06134102
• Ruxolitinib Adherence in Myelofibrosis and Polycythemia VeraCompletedNCT06078319
• A Study to Evaluate P1101 in Japanese PV PatientsCompletedNCT06002490Phase 3
• A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia VeraCompletedNCT05853445
• Tracing Changed Production of Red Blood CellsCompletedNCT05833477Not applicable
• Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical PracticeStatus unknownNCT05566535
• Late Gestational Diabetes Mellitus Diagnosis in Obese WomenStatus unknownNCT05510518
• Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with ErythrocytosisCompletedNCT05487794Not applicable
• A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVActive, not recruitingNCT05481151Phase 3
• Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.CompletedNCT05421104
• StatStrip Lactate, Hemoglobin, and Hematocrit Meter in Whole BloodTerminatedNCT05118048
• Safety Evaluation Study for Patients With Polycythemia VeraStatus unknownNCT05074550Phase 1
• A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT05044026
• A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaWithdrawnNCT04896112Phase 1
• PTG-300 in Patients With Polycythemia Vera and Elevated HematocritCompletedNCT04767802Phase 2
• HIGH Altitude CArdiovascular REsearch Latin America Population StudyCompletedNCT04751292
• A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentActive, not recruitingNCT04576156Phase 3
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2

← Polycythemia overview